Electromed, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Electromed develops, manufactures and markets SmartVest high-frequency chest wall oscillation airway-clearance systems for home care, institutional and international markets. This unaudited Form 10-Q covers the three and six months ended December 31, 2021, the second quarter and first six months of fiscal 2022.
Financial Performance and Position
| Metric | Three Months Ended Dec. 31, 2021 | Prior Year | Six Months Ended Dec. 31, 2021 | Prior Year |
|---|---|---|---|---|
| Net revenues | $10.248 million | $9.496 million | $20.249 million | $17.500 million |
| Gross profit | $7.880 million | $7.525 million | $15.581 million | $13.673 million |
| Gross margin | 76.9% | 79.2% | 76.9% | 78.1% |
| Operating income | $1.076 million | $1.583 million | $1.614 million | $2.245 million |
| Net income | $0.838 million | $1.204 million | $1.277 million | $1.738 million |
| Diluted EPS | $0.10 | $0.13 | $0.15 | $0.19 |
- Second-quarter operating margin was approximately 10.5% and net margin approximately 8.2%; six-month operating margin was approximately 8.0% and net margin approximately 6.3%.
- Revenue mix for the six months was home care $18.688 million, institutional $0.782 million, home care distributor $0.543 million and international $0.236 million.
- Cash was $10.470 million at December 31, 2021, compared with $11.889 million at June 30, 2021. Working capital was $27.780 million.
- Net cash used in operating activities was $0.106 million for the six months, versus $1.491 million provided in the prior-year period. Accounts receivable increased $2.082 million, primarily reflecting Medicare-related growth and its 13-month payment cycle.
- Investing cash outflows were $0.580 million, including $0.511 million for property and equipment and $0.069 million for finite-life intangible assets.
- Financing cash outflows were $0.733 million, including $0.663 million for share repurchases and $0.070 million for taxes on net share settlements.
- The company had no outstanding borrowings and the full $2.5 million revolving credit facility was available. The facility expires December 18, 2023, subject to renewal, and bears interest at prime less 1.00%.
- Total liabilities were $4.717 million and shareholders’ equity was $33.487 million at December 31, 2021.
Material Changes Versus the Prior Comparable Period
- Second-quarter revenue increased 7.9% to $10.248 million; six-month revenue increased 15.7% to $20.249 million.
- Home care revenue increased 5.6% in the quarter and 14.2% year to date, driven primarily by higher referrals and approvals, sales-force execution, the CMS waiver and additional direct sales representatives.
- Institutional revenue increased 7.8% in the quarter and 33.2% year to date as hospitals resumed HFCWO utilization and increased capital purchases and disposable volumes.
- Home care distributor revenue increased 159.7% in the quarter and 66.6% year to date, primarily due to higher orders from one distribution partner.
- Gross margin declined because of higher raw-material and shipping costs.
- SG&A increased 19.1% in the quarter and 27.0% year to date, reflecting higher personnel, travel, incentive compensation, systems infrastructure investment and, in the six-month period, shareholder activism costs.
- Net income declined 30.4% in the quarter and 26.5% year to date, despite revenue growth, primarily because of increased strategic operating investments, higher costs and shareholder activism expenses incurred in the first quarter.
- The company repurchased 55,687 shares for $0.663 million during the six months. The remaining authorization was approximately $1.258 million at December 31, 2021.
Guidance, Outlook, Risks and Unusual Items
- No specific revenue or earnings guidance is provided in the filing. Management stated that existing working capital, operating cash flows and available borrowing capacity are expected to provide adequate liquidity during fiscal 2022.
- COVID-19 and the Omicron variant continued to restrict face-to-face clinic access and could affect sales, operations and supply chains. Management expects pandemic effects to continue during the remainder of fiscal 2022.
- The company observed longer supply-chain timelines and higher raw-material and shipping costs, with additional increases expected, particularly for electronic components. These pressures could reduce gross margins or impair product availability.
- A CMS waiver easing certain Medicare documentation and face-to-face requirements was extended for 90 days beginning January 16, 2022, but was expected to expire in April 2022. Expiration could reduce referrals and approval rates, although management expects improved clinic access and sales execution to mitigate the impact.
- The company completed efforts to comply with federal contractor vaccination requirements with minimal disruption.
- A putative class action lawsuit related to a previously disclosed data breach was filed in September 2021. The company moved to dismiss the complaint and states that it cannot determine the ultimate outcome or potential loss exposure.
- Key risks include reimbursement-policy changes, competition, regulatory compliance, supply-chain disruption, cybersecurity incidents, international-market volatility, sales-force expansion and renewal or availability of credit.
- Management reported effective disclosure controls and procedures and no material changes to internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Whether Medicare and other payer reimbursement trends remain favorable after the CMS waiver expires.
- The sustainability of revenue growth, particularly the concentration of growth in home care and the increase from one distributor.
- The effect of raw-material, freight and labor inflation on gross margin.
- Conversion of the significant accounts-receivable balance into cash, given the Medicare payment cycle and variable consideration estimates.
- Progress, cost and expected benefits of the ERP, customer relationship management and revenue-cycle management investments.
- The resolution and potential financial exposure of the data-breach class action.
- Compliance with credit-facility covenants and continued availability of the $2.5 million revolving facility.